Share Email Print

Proceedings Paper

Studies of a novel photosensitizer Pd-bacteriopheophorbide (Tookad) for the prostate cancer PDT in canine model
Author(s): Zheng Huang; Qun Chen; Pierre-Herve Brun; Brian C. Wilson; Avigdor Scherz; Yoram Salomon; David L. Luck; Jill Beckers; Fred W. Hetzel
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Photodynamic therapy (PDT) mediated with vascular acting photosensitizer pd-bacteriopheophorbide (Tookad), is investigated as an alternative modality for the total ablation of prostate cancer. In vivo normal canine prostate is used as the animal model. Interstitial PDT was performed by irradiating the surgically exposed prostates with a diode laser (763 nm, 150 mW/cm) to activate the i.v. infused photosensitizer drug. The effects of two-session PDT were evaluated. The prostate and its adjacent tissues were harvested and subjected to histopathological examination. At one-week, post second-session PDT, the animals recovered well with little or no urethral complications. Prostatic urethra and prostate adjacent tissues (bladder and underlying colon) were well preserved. Two-session PDT or one single session PDT induced a similar extent of damage. PDT induced prostate lesions were characterized by marked hemorrhagic necrosis. Maximum lesion size of over 3 cm in dimension could be achieved with a single 1-cm interstitial treatment, suggesting the therapy is very effective in ablating prostatic tissue. Pharmacokinetic studies show that the photosensitizer is cleared rapidly from the circulation. In conclusion, the novel photosensitizer Tookad mediated PDT may provide an effective alternative to treat prostate cancer.

Paper Details

Date Published: 8 December 2003
PDF: 8 pages
Proc. SPIE 5254, Third International Conference on Photonics and Imaging in Biology and Medicine, (8 December 2003); doi: 10.1117/12.546099
Show Author Affiliations
Zheng Huang, HealthONE Alliance (United States)
Qun Chen, HealthONE Alliance (United States)
Pierre-Herve Brun, STEBA BIOTECH (France)
Brian C. Wilson, Ontario Cancer Institute (Canada)
Avigdor Scherz, Weizmann Institute of Science (Israel)
Yoram Salomon, Weizmann Institute of Science (Israel)
David L. Luck, HealthONE Alliance (United States)
Jill Beckers, HealthONE Alliance (United States)
Fred W. Hetzel, HealthONE Alliance (United States)

Published in SPIE Proceedings Vol. 5254:
Third International Conference on Photonics and Imaging in Biology and Medicine
Qingming Luo; Valery V. Tuchin; Min Gu; Lihong V. Wang, Editor(s)

© SPIE. Terms of Use
Back to Top